(thirdQuint)MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma.

 This study will look at the dose-limiting toxicity and response to treatment in participants who take MLN1117 in combination with TAK-659, paclitaxel or docetaxel or investigational TAK-659 or investigational alisertib.

 The study will enroll approximately 60 participants in the dose escalation phase (Part 1) and 118 participants in the dose expansion phase (Part 2).

 Participants will be randomly assigned to 1 of the 4 treatment groups: - MLN1117 + TAK-659 - MLN1117 + alisertib - MLN1117 + paclitaxel - MLN1117 + docetaxel In Part 1, dose of MLN1117 will be increased step by step.

 All participants will be asked to take tablets of MLN1117 for 3 days on and 4 days off per week in 28-day treatment cycles or 21-day treatment cycles when given in combination with the other companion drugs.

 This multi-centre trial will be conducted worldwide.

.

 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma@highlight

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma.

 The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).

